Drug Research

Agreement to buy F-Star Alpha and its lone asset, FS102 between Bristol-Myers Squibb and F-star Alpha has been terminated. Bristol-Myers Squibb and F-star Alpha, entered into an…
Read More...

Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease…
Read More...

Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug…
Read More...

MEDITE Cancer Diagnostics specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis…
Read More...

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who…
Read More...

Servier and CTI BioPharma Corp.  jointly announced that they will expand their existing license and development collaboration agreement for PIXUVRI (pixantrone). Under the expanded…
Read More...

According to the study published in the journal of the American Academy of Ophthalmology, the researchers used deep-learning methods to create an automated algorithm to detect diabetic…
Read More...

AstraZeneca announced that the European Commission (EC) has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of adult…
Read More...

DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, has acquired 3D printing technology from Tissue Regeneration Systems, Inc. (TRS). The 3D printing…
Read More...

H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology…
Read More...

ReForm Biologics, a pharmaceutical technology company that develops proprietary excipients to improve biologic formulations, announced that the Company’s Board of Directors has…
Read More...

The US Food and Drug Administration (FDA) has scheduled Puma Biotechnology’s New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee (ODAC) on…
Read More...

Roche interim results from the phase III HAVEN 2 study shows emicizumab prophylaxis showed a clinically meaningful reduction in the number of bleeds in children less than 12 years of…
Read More...

Ionis Pharmaceuticals announced its collaboration and license agreement with Suzhou Ribo Life Science Co., Ltd. (Ribo) to develop and commercialize RNA-targeted therapeutics in China.…
Read More...

Rigel Pharmaceuticals announced that it has submitted a NDA (New Drug Application) to the U.S. Food and Drug Administration (FDA) for fostamatinib in patients with chronic and…
Read More...

Zymeworks announced that its lead product candidate, ZW25, has been granted orphan drug designation from the U.S. Food and Drug Administration (the “FDA”) in the treatment of gastric…
Read More...

Immune Therapeutics a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal, its proprietary formulation of lower-dose naltrexone,…
Read More...

Digital diabetes management platform GlucoMe announced the appointment of John Erickson as EVP, General Manager North America. In this role, John will be responsible for leading the…
Read More...

Second Sight Medical Products, Inc. a developer, manufacturer and marketer of implantable visual prosthetics that are intended to provide some useful vision to blind patients announced…
Read More...

Lyndra, Inc. announced the closing of a $23 Million Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink…
Read More...